Powder-Filled Hard Gelatin Capsules Market

USD 5.9 billion in 2026 to USD 10.1 billion by 2036 at a 5.5% CAGR.

• The Powder-Filled Hard Gelatin Capsules Market reached USD 5.6 billion in 2025.
• Demand is projected to increase from USD 5.9 billion in 2026 to USD 10.1 billion by 2036.
• The market is forecast to record 5.5% CAGR from 2026 to 2036 as pharmaceutical formulators and nutraceutical brands rely on familiar oral solid-dose formats.

What are the defining numbers behind Powder-Filled Hard Gelatin Capsules Market growth?

An absolute opportunity of USD 4.2 billion is expected between 2026 and 2036.

• Demand Drivers in the Market
  • Pharmaceutical formulators need capsule shells that handle dry powders consistently because filling accuracy affects dose release and batch acceptance.
  • Prescription-drug channels support capsule demand. CMS reported that U.S. retail prescription drug spending increased 7.9% to USD 467.0 billion in 2024.
  • Capsule producers need stable gelatin sourcing owing to demand from Type A gelatine capsules and familiar immediate-release products.
  • Nutraceutical brands use hard capsules for powders that need portion control, neutral taste masking and simple consumer handling.
• Key Segments Analyzed
  • By Product: Type A Gelatine Capsules are expected to hold 68.70% share in 2026 because pork skin gelatine offers common shell-forming behavior for powder-filled formats.
  • By Capsule Size: 000 Capsule Size is projected to account for 56.40% share in 2026 as high-fill products need larger internal volume per unit.
  • By Dosage System: Immediate Release Capsules are anticipated to capture 39.50% share in 2026 since conventional release remains the default route for many dry-powder drugs.
  • By Application: Antibacterial Drugs are estimated to represent 45.20% share in 2026 due to steady use of capsule-based systemic antibacterial therapies.
  • By End Use: Pharmaceutical Industry is forecast to hold 21.00% share in 2026 owing to validated filling lines and regulated oral solid-dose portfolios.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “Hard gelatin capsules keep a practical role where powders need clean filling and predictable disintegration. The market is expected to favor suppliers that prove shell consistency, moisture control and filling-machine compatibility. Producers that pair gelatin know-how with documentation support are better placed for regulated pharmaceutical accounts.”
• Strategic Implications
  • Capsule manufacturers should document gelatin source, bloom strength and moisture range so pharmaceutical customers can shorten qualification work.
  • Drug makers should align capsule size with powder density early because late size changes affect packaging and patient handling.
  • U.S.-focused suppliers should track the January 2026 USITC hard-empty-capsule decision, which led to antidumping and countervailing duty orders on imports from Brazil, China, India and Vietnam and may influence sourcing decisions.
  • Nutraceutical brands should match capsule opacity, color and fill capacity to powders that need taste masking and shelf presentation.

USA is projected to post 6.1% CAGR through 2036 because prescription-drug spending and domestic supply are expanding together. Germany is expected to record 5.7% supported by high pharmaceutical expenditure. France is anticipated to advance at 5.2% due to reimbursed pharmacy volume. Italy is estimated to hold 4.6% owing to medicine spending. Spain is forecast to register 4.1% as prescription financing supports oral-dose demand.

Type A Gelatine Capsules lead Product at 68.70%; 000 Capsule Size leads Capsule Size at 56.40%.

Which Product dominates?

Type A Gelatine Capsules are expected to hold 68.70% share in 2026.

Type A Gelatine Capsules are expected to hold 68.70% share in 2026 because pork skin gelatine gives capsule makers a familiar material base. Type B specifications fit selected customer quality programs. Shell performance depends on moisture balance, disintegration behavior and filling equipment compatibility.

What leads the Capsule Size segment?

000 Capsule Size is projected to account for 56.40% share in 2026.

000 Capsule Size is projected to account for 56.40% share in 2026 as large fill capacity reduces unit count for bulky powders. The 00 size supports medium-high fill needs. Size 0 and size 1 remain useful where swallowing comfort shapes product design. Spain’s Ministry of Health reported on December 18, 2025 that generic medicines accounted for 47.4% of medicine packages dispensed through SNS prescriptions in 2024.

How does Dosage System shape demand?

Immediate Release Capsules are anticipated to lead with 39.50% share in 2026.

Immediate Release Capsules are anticipated to lead with 39.50% share in 2026 since conventional release is familiar to formulators and filling-line teams. Sustained release capsules support controlled-release systems where dose timing needs extension. Delayed release capsules serve enteric applications. Magnetically controlled capsules remain tied to targeted delivery and research formulation work.

What supports Antibacterial Drugs within Application?

Antibacterial Drugs are estimated to represent 45.20% share in 2026.

Antibacterial Drugs are estimated to represent 45.20% share in 2026 because systemic antibacterial products often use powders that fit hard capsules. Anticancer drugs, anti inflammatory drugs and analgesics expand the application mix.

What supports Pharmaceutical Industry within End Use?

Pharmaceutical Industry is forecast to hold 21.00% share in 2026.

Pharmaceutical Industry is forecast to hold 21.00% share in 2026 owing to validated capsule filling lines and regulated release testing. Prescription pharmaceuticals use hard capsules where powder flow and shell integrity match batch requirements. Over the counter products add volume where consumers prefer capsules. Nutraceutical use remains meaningful for taste masking and portion control.

Oral solid-dose demand drives it; gelatin-source sensitivity restrains it.

Drivers Impact Analysis

Opportunity Impact Analysis

Restraints Impact Analysis

• The country comparison spans 2.0 percentage points and forms three practical growth bands across the forecast period.
• The USA remains 0.4 percentage point above Germany through prescription-drug spending and domestic capsule investment.
• Germany remains 0.5 percentage point above France as pharmaceutical health expenditure supports regulated oral-dose supply.
• France remains 0.6 percentage point above Italy through reimbursed pharmacy volume and common oral medicines.
• Italy remains 0.5 percentage point above Spain as medicine spending and local output support capsule demand.
• Spain closes the displayed range through prescription financing and clinical-trial activity.

Comparable CAGRs create different entry conditions due to drug spending, reimbursement policy, local manufacturing and supplier qualification. Full report coverage includes North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa.

What supports USA adoption?

6.1% CAGR, supported by prescription-drug pipelines and regional capsule supply.

FDA CDER approved 46 novel drugs in 2025 across a broad range of therapeutic areas, providing a continued pipeline for drug-development and formulation activity. The USA is projected to record 6.1% CAGR through 2036 as capsule makers serve prescription products and supplement brands. ACG’s Atlanta investment gives domestic users a closer hard-shell capsule source for future batches.

How is Germany scaling demand?

5.7% CAGR, driven by medicine expenditure and regulated pharmaceutical supply.

German capsule demand is tied to a large reimbursed medicine base and high quality expectations in pharmaceutical manufacturing. Germany is expected to record 5.7% CAGR through 2036. Destatis reported on April 2, 2026 that expenditure on pharmaceuticals in Germany increased 9.3% to EUR 85.1 billion in 2024. This spending scale provides context for the substantial domestic market for pharmaceutical products and related dosage-form development.

What supports France growth?

5.2% CAGR, backed by reimbursed pharmacy volume and routine oral medicines.

France keeps a broad pharmacy channel for common medicines that can be supplied as capsules when powder fill and release needs align. The market is anticipated to post 5.2% CAGR through 2036. Assurance Maladie reported in January 2026 that more than 430 million boxes of paracetamol were reimbursed in France in 2024, highlighting the substantial volume of commonly used medicines dispensed through community pharmacies.

What is supporting Italy outlook?

4.6% CAGR, led by medicine spending and local pharmaceutical output.

Italian manufacturers and contract formulators use hard gelatin capsules where powders need familiar handling on oral solid-dose lines. Italy is estimated to hold 4.6% CAGR through 2036. AIFA reported in August 2026 that total pharmaceutical spending in Italy reached EUR 39.3 billion in 2025, providing context for the scale of the domestic pharmaceutical market and associated dosage-form demand.

How does Spain perform?

4.1% CAGR, shaped by prescription financing and clinical-trial activity.

Spain combines public prescription financing with clinical research activity that supports capsule use in development and commercial products. Spain is forecast to register 4.1% CAGR through 2036. AEMPS reported in June 2026 that 962 clinical trials involving human medicines were authorized in Spain in 2025, highlighting the scale of the country’s clinical-research activity.

Directly relevant hard-capsule suppliers include ACG, Qualicaps, Suheung and CapsCanada, supported by current hard-capsule product portfolios.

ACG Worldwide is active across hard-shell capsules and solid-dosage systems. Its October 2025 USD 200 million U.S. investment includes new manufacturing capacity for gelatin and HPMC hard-shell capsules, strengthening its direct relevance to hard-capsule dosage forms. Qualicaps remains relevant through pharmaceutical-grade two-piece hard capsules suitable for formulations including dry powders and pellets, supported by global pharmaceutical customer coverage. Suheung Co. Ltd. participates through cGMP-compliant empty hard-capsule manufacturing and broader pharmaceutical and nutraceutical product capabilities.

CapsCanada Corporation, Qingdao Yiqing Medicinal Capsules Co. Ltd. and Shanxi Guangsheng Medicinal Capsules Co. Ltd. broaden the supplier set. Healthcaps India Ltd., Roxlor, Sunil Healthcare Ltd., and Natural Capsules Ltd. add regional coverage. Competition is expected to center on shell consistency, documentation, fill-machine performance and supply reliability.

Directly relevant suppliers include ACG, Qualicaps, Suheung Co. Ltd. and CapsCanada Corporation. Regional hard-capsule manufacturers broaden the company set.

• ACG Worldwide
• Qualicaps
• Suheung Co. Ltd.
• CapsCanada Corporation
• Qingdao Yiqing Medicinal Capsules Co.Ltd.
• Shanxi Guangsheng Medicinal Capsules Co.Ltd
• Healthcaps India Ltd.
• Roxlor
• Sunil Healthcare Ltd.
• Natural Capsules Ltd.

• ACG. (2025, October 17). ACG to invest $200 million in U.S. hard-shell capsule manufacturing.
• Agencia Española de Medicamentos y Productos Sanitarios. (2026, June 2). La AEMPS presenta los principales hitos de 2025 en su Memoria de Actividades.
• Agenzia Italiana del Farmaco. (2026, August 6). AIFA pubblica il Rapporto OsMed 2025 “L’uso dei Farmaci in Italia”.
• Assurance Maladie. (2026, January 14). Chiffres-clés du médicament en France : des évolutions profondes sur la décennie.
• Statistisches Bundesamt. (2026, April 2). Health expenditure by functions of health care.
• Ministerio de Sanidad. (2025, December 18). El gasto en receta médica del Sistema Nacional de Salud alcanzó los 13.865 millones de euros, un 4,9% más que en 2023.
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2026, January). Advancing health through innovation: New drug therapy approvals 2025 [Report].
• U.S. International Trade Commission. (2026, January 16). Hard empty capsules from Brazil, China, India, and Vietnam injure U.S. industry, says USITC.

• The report explains powder-filled hard gelatin capsule use across product, capsule size and dosage system.
• Segment analysis identifies Type A Gelatine Capsules and 000 Capsule Size as 2026 reference points.
• Country analysis examines the USA, Germany, France, Italy and Spain using drug spending and manufacturing context.
• Competitive analysis reviews ACG Worldwide, Qualicaps, Suheung Co. Ltd., CapsCanada Corporation and regional capsule suppliers.
• Application analysis covers antibacterial drugs, anticancer drugs, anti inflammatory drugs, analgesics and other oral-dose uses.
• The forecast uses official source review, company portfolio checks and interviews across capsule supply roles.

The Powder-Filled Hard Gelatin Capsules Market covers two-piece hard gelatin shells filled with powders for oral-dose products. It includes Type A and Type B gelatine capsules, capsule sizes from 000 to 3, and release systems ranging from immediate release to targeted delivery formats.

The market differs from broader pharmaceutical packaging materials because the scope centers on powder-filled hard gelatin capsule formats. Empty capsule shells, filled capsules and related filling-line compatibility are included when they support the defined powder-filled capsule format.

What is included in the scope?

The scope includes powder-filled hard gelatin capsules used in prescription products, dietary supplements and research batches. It covers Type A and Type B gelatine capsules across immediate, sustained, delayed and magnetically controlled release systems. Related coverage includes pharmaceutical capsule filling machines, dietary supplements, bovine gelatin and powder-filled hard gelatin capsules.

What is excluded from the scope?

Softgel capsules, tablets, sachets, bottles and raw gelatin sold as a food ingredient are outside the scope. Softgel capsules coverage remains an adjacent reference where liquid-fill encapsulation differs from powder-filled hard capsule use.

Capsule filling machines are outside the revenue boundary when sold as standalone capital equipment. Gelatin raw material sales are included only when linked to capsule shell manufacturing for powder-filled hard gelatin capsule products.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Discussions with capsule manufacturers, pharmaceutical formulators, supplement brands, distributors and research laboratories examine shell choice, fill performance and supplier approval paths.
• Desk Research: Desk research covers government statistics, regulatory publications, company releases, product portfolios, trade decisions and official health-expenditure data.
• Market Sizing and Forecasting: Estimates combine historical performance, capsule size mix, application shares, country growth, supplier participation and barriers to wider acceptance.
• Data Validation and Update Cycle: Findings are validated against public data, company activity, regulatory changes and product availability. Updates review investments, portfolio changes and clinical activity.

• By Product

  • Type A Gelatine Capsules
  • Type B Gelatine Capsules

• By Capsule Size

  • 000 Capsule Size
  • 00 Capsule Size
  • 0 Capsule Size
  • 1 Capsule Size
  • 3 Capsule Size

• By Dosage System

  • Immediate Release Capsules
  • Sustained Release Capsules
  • Delayed Release Capsules
  • Magnetically Controlled Capsules

• By Application

  • Antibacterial Drugs
  • Anticancer Drugs
  • Anti Inflammatory Drugs
  • Analgesics
  • Cardiovascular Drugs
  • Cough And Cold Drugs
  • Antacid And Anti Flatulent Drugs
  • Antiemetics

• By End Use

  • Pharmaceutical Industry
  • Nutraceutical Industry
  • Cosmetic Industry
  • Research Laboratories

• By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa